2.38%
1.35%
-14.66%
4.49%
56.42%
33.56%
418.15%
AI Spotlight on PTGX
Company Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases.It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications.The company has a license and collaboration agreement with Janssen Biotech, Inc.
Protagonist Therapeutics, Inc.was incorporated in 2006 and is headquartered in Newark, California.
Market Data
| Last Price | 39.12 |
| Change Percentage | 2.38% |
| Open | 38.67 |
| Previous Close | 38.21 |
| Market Cap ( Millions) | 2331 |
| Volume | 333508 |
| Year High | 48.89 |
| Year Low | 24.22 |
| M A 50 | 39.99 |
| M A 200 | 38.24 |
Financial Ratios
| FCF Yield | 9.83% |
| Dividend Yield | 0.00% |
| ROE | 34.68% |
| Debt / Equity | 2.05% |
| Net Debt / EBIDTA | -79.40% |
| Price To Book | 4.54 |
| Price Earnings Ratio | 14.14 |
| Price To FCF | 10.17 |
| Price To sales | 7.2 |
| EV / EBITDA | 14.6 |
News
- Jan -13 - Protagonist: Rusfertide PV Data Q1 2025 Isn't The Only 2025 Catalyst On Deck
- Jan -06 - Protagonist Therapeutics Reports Granting of Inducement Awards
- Dec -19 - Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025
- Nov -22 - Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024
- Nov -19 - Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate
- Nov -07 - Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates
- Nov -07 - Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update
- Nov -05 - Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting
- Sep -10 - Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines
- Sep -03 - Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
- Aug -06 - Protagonist Therapeutics (PTGX) Reports Q2 Loss, Misses Revenue Estimates
- Aug -06 - Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- Jul -31 - Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor
- Jul -22 - Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024
- Jul -18 - Protagonist Therapeutics (PTGX) is on the Move, Here's Why the Trend Could be Sustainable
- Jul -11 - 3 Growth Stocks No One Is Watching (But They Should Be)
- Jun -05 - The 3 Best Biotech Stocks to Buy in June 2024
- May -31 - Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024
- May -14 - Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress
- May -07 - Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Peptide-based Therapeutics
Expected Growth : 8.97 %
What the company do ?
Peptide-based Therapeutics from Protagonist Therapeutics, Inc. are novel, orally stable, gut-restricted, peptide therapeutics for inflammatory bowel disease and other diseases.
Why we expect these perspectives ?
Protagonist Therapeutics' peptide-based therapeutics growth is driven by increasing demand for targeted therapies, rising prevalence of chronic diseases, and advancements in peptide engineering. The company's proprietary technology enables development of novel, orally stable peptides, addressing unmet needs in inflammatory bowel disease and other indications, fueling growth.
Protagonist Therapeutics, Inc. Products
| Product Range | What is it ? |
|---|---|
| PTG-300 | PTG-300 is a hepcidin mimetic peptide and a potential treatment for beta-thalassemia and myelodysplastic syndrome. |
| PTG-200 | PTG-200 is a injectable hepcidin mimetic peptide and a potential treatment for hereditary hemochromatosis. |
| PTG-400 | PTG-400 is an oral hepcidin mimetic and a potential treatment for iron deficiency anemia. |
Protagonist Therapeutics, Inc.'s Porter Forces
Threat Of Substitutes
The threat of substitutes for Protagonist Therapeutics, Inc. is medium due to the presence of alternative treatments and therapies for cancer and rare genetic disorders.
Bargaining Power Of Customers
The bargaining power of customers for Protagonist Therapeutics, Inc. is low due to the lack of negotiating power of individual patients and the high demand for innovative treatments.
Bargaining Power Of Suppliers
The bargaining power of suppliers for Protagonist Therapeutics, Inc. is medium due to the presence of multiple suppliers for raw materials and equipment, but the high cost of switching suppliers.
Threat Of New Entrants
The threat of new entrants for Protagonist Therapeutics, Inc. is high due to the increasing interest in biotechnology and the availability of funding for startups.
Intensity Of Rivalry
The intensity of rivalry for Protagonist Therapeutics, Inc. is high due to the presence of established competitors and the high stakes in the biotechnology industry.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 0.34% |
| Debt Cost | 3.95% |
| Equity Weight | 99.66% |
| Equity Cost | 14.30% |
| WACC | 14.26% |
| Leverage | 0.34% |
Protagonist Therapeutics, Inc. : Quality Control
Protagonist Therapeutics, Inc. passed 7 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| IMNM | Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of … |
| PRAX | Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive … |
| YMAB | Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers … |
| GTHX | G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which … |
| CDXC | ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Protagonist Therapeutics
A-Score
1-Year Total Return ->
🥈
Praxis Precision Medicines
A-Score
1-Year Total Return ->
🥉
G1 Therapeutics
A-Score
1-Year Total Return ->
4
Y-mAbs Therapeutics
A-Score
1-Year Total Return ->
5
ChromaDex
A-Score
1-Year Total Return ->
6
